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Respiratory tract infections, the majority of which are community-acquired, are among the leading 
causes of death worldwide and a leading indication for hospital admission. The burden of disease 
demonstrates a “U” shaped distribution, primarily affecting young children as the immune system 
matures, and older adults as the process of immunosenescence and accumulation of co-morbidities 
leads to increased susceptibility to infection.  
Diagnosis of community-acquired pneumonia is traditionally based on demonstration of a new 
infiltrate on a chest radiograph in a patient presenting with an acute respiratory illness or sepsis. 
Advances in diagnosis have been slow, and although there are increasing data on the value of 
computed tomography or lung ultrasound as more sensitive diagnostic methodologies, they are not 
widely used as initial diagnostic tests. There are a wide range of differential diagnoses and 
pneumonia “mimics” which should be considered in patients presenting with CAP.  
Once the diagnosis of CAP has been made, identifying the causative microorganism is the next stage 
in the diagnostic process. Traditional culture based approached are relatively insensitive and achieve 
a positive diagnosis in only 30-70% of cases, even when rigorously applied. Urinary antigen tests, 
polymerase chain reaction assays and even next generation sequencing technologies have become 
available and are increasing the rates of positive diagnosis.  
In an era of increasing antimicrobial resistance, the accurate diagnosis of CAP and determining the 
causative pathogen are ever more important. Getting these both right are the key steps to both 
reducing morbidity and mortality from CAP and appropriate antimicrobial stewardship which is now 
an international healthcare priority.  
 
 
 
Introduction 
Acute respiratory tract infections are the leading cause of death in developing countries, while 
remaining a leading cause of death in developed nations.(1,2) The Global Burden of Disease study 
revealed that the number of deaths from acute respiratory tract infections has fallen over the past 2 
decades. Nevertheless, respiratory infections will continue to have a profound impact 
worldwide.(1,2) The exact prevalence of acute respiratory tract infections worldwide is nearly 
impossible to calculate, but there are an estimated 4 million deaths per year, with up to ¾ of those 
deaths being in children under the age of 5.  
Determining the precise impact of community-acquired pneumonia (CAP) worldwide is made more 
difficult by the use of a definition that relies on chest radiographic evidence of consolidation.(3-5) It 
is estimated that up to 80% of episodes of CAP in developed countries are treated without the 
patient ever receiving a chest x-ray. In developing nations, this proportion will be higher still.(5-7)  
Whether in primary care or in the hospital setting, CAP must be quickly recognised and treated, as 
severe CAP can be life threatening.(8) In the emergency setting, prompt resuscitation and 
administration of intravenous antibiotics are essential steps in reducing the morbidity and mortality 
from CAP which stands at 5-15% for hospitalised patients and often >25% for patients requiring 
admission to an intensive care unit.(8-10) In this context, CAP must be differentiated from other 
conditions causing acute respiratory failure and septic shock. In the less acute setting, in outpatients 
or in primary care, the challenge is more to differentiate patients with CAP who may benefit from 
antibiotic therapy, from that much larger group of patients with acute cough who will not.(5,7,11,12) 
Once the diagnosis of CAP has been made, antibiotic treatment is commenced according to the 
severity of disease and to cover the most likely causative pathogens.(13,14) Testing to determine the 
possible causative pathogen serves a number of important functions include 1- to de-escalate initial 
broad-spectrum antibiotic treatment if a pathogen is identified that can be treated with narrower 
spectrum therapy (15) 2- to identify unusual or drug resistant pathogens that will not be covered by 
the initial empirical regime(16) 3- to provide local data on the frequency of different causative 
pathogens and antibiotic resistant rates that can be used to guide future empirical treatment 
guidelines.(17) 
The goal of this review is to discuss the diagnostic approach in CAP, with a focus on how to make the 
initial diagnosis and the emerging methods for determining the underlying pathogen. 
 
What is community-acquired pneumonia? 
By convention, pneumonia is an acute respiratory illness associated with a new infiltrate on the 
chest radiograph.(13) In practice, pneumonia is an extremely heterogeneous clinical disorder. While 
many patients present with classic symptoms of a combination of cough, sputum production, 
breathlessness, fever and pleuritic chest pain, many patients do not. Particularly in the elderly, fever 
may be absent, and pneumonia may present with episodes of decreased mobility, delirium, acute 
cardiac disorders (such as new onset atrial fibrillation) or abdominal pain without obvious 
respiratory symptoms.(18) Pneumonia is the most common cause of community acquired sepsis 
along with urinary tract infections and should be considered in all patients presenting with the 
clinical syndrome of sepsis.  
Pneumonia is divided into community and hospital acquired.(17) Arbitrarily, HAP is considered to be 
present if pneumonia developed >48 hours after admission to a hospital or healthcare environment, 
with all other cases of pneumonia being considered community-acquired.(19) The causative 
pathogens in community-acquired pneumonia are typically upper respiratory tract commensals and 
include Gram-positive organisms (most frequently Streptococcus pneumoniae, but also 
Staphylococcus aureus), Gram-negative organisms (most frequently Haemophilus influenzae, but 
also less frequently Moraxella catarrhalis and the enterobacteriaceae or Pseudomonas aeruginosa) 
and the atypical pathogens (including Legionella pneumophila, Mycoplasma pneumoniae and 
others.(20,21) Viruses are increasingly recognised as the cause of CAP, and may be detected in 
patients with an identified bacterial pathogen or in those without an identified bacteria.(22) Fungi 
are not, thus far, identified as a common cause of CAP in immunocompetent adults.  
In contrast, the causative pathogens in HAP are most frequently organisms such as Methicillin 
resistant Staphylococcus aureus, Pseudomonas aeruginosa, enterobacteriaceae with atypical 
pathogens being rare.(17,19) 
This classical dichotomy hides a much greater degree of complexity. Among patients with CAP, there 
are patients with few co-morbidities who are at very low risk of antibiotic resistant pathogens and are 
most likely to have pneumococcal or atypical pneumonia.(16,17) In contrast, among elderly patients 
and those with co-morbidities atypical pathogens are uncommon, but the incidence of 
enterobacteriaceae and Pseudomonas aeruginosa increases sharply.(23,24) Other groups deserve 
special mention. Patients with HIV and those with other forms of immunosuppression may be at risk 
of opportunistic pathogens not typically considered in CAP therapy.(25) This leads many authors to 
suggest that CAP with immunosuppression should be regarded as a separate clinical entity.(26) 
Patients with HIV are at significantly increased risk of CAP, but in the era of highly active anti-retroviral 
therapy the most frequent aetiological agent is S. pneumoniae, as with CAP not associated with HIV. 
Pneumocystis jirovecii is the most frequent aetiology in patients with a CD4 count <200 per 
mm3.(25,27)   
Similarly, the lines between community and hospital are increasingly blurred as the population ages 
and healthcare is delivered increasingly in the community. Nursing home acquired pneumonia 
(NHAP) has been proposed as a separate entity, but at least in Europe there is little evidence that 
they require different empirical therapy.(28) A study from Germany compared 518 patients with 
NHAP and 2569 CAP patients and found only minor differences in aetiology- with more S. aureus and 
less atypical pathogens in the NHAP group. Differences in outcome were due to worse functional 
status and co-morbidities in NHAP rather than differences in bacteriology.(28,29) Similar results 
have been reported from Spain and elsewhere.(28,29)   
The concept of healthcare associated pneumonia was proposed in 2005 by the IDSA/ATS HAP/VAP 
guidelines as a means of dealing with this increasing complexity.(17,19) Their proposal to treat 
patients from nursing homes, those with prior hospitalisation or prior antibiotic treatment and other 
risk factors as HAP patients led to 20-30% of those previously regarded as CAP being treated with 
broad-spectrum antibiotic therapy.(19,30,31) Recent data from the United States suggests that 
approximately 30% of community-acquired pneumonia is now being treated with anti-MRSA 
directed therapy, despite the prevalence of MRSA being approximately 1% in this group.(19,30,31) 
There is a consensus that while the HCAP criteria represent risk factors for a different spectrum of 
pathogens, they did not function as a method of selecting empirical antibiotic treatment, leading to 
overtreatment.(19,23,26,32) Revision of this guidance is currently underway.  
Thus the classification of pneumonia remains into CAP and HAP, but recognises that within CAP 
there are subgroups of patients that will require additional investigation and consideration of a 
different spectrum of causative pathogens.  (figure 1)  
 
Figure 1. Classification of pneumonia. Abbreviations CAP= community-acquired pneumonia, HAP= 
hospital acquired pneumonia, MDR= multidrug resistant. NHAP= nursing home acquired pneumonia.  
 
The risk factors for multidrug resistant pathogens are dealt with more extensively in another review 
in this series but are strongly linked to age, multimorbidity, co-morbidities such as respiratory 
disease, dementia and renal failure, and antibiotic use.(33-35) 
 
Diagnosis of CAP in the hospital setting 
As described above, in practical terms CAP should be diagnosed in patients with acute respiratory 
symptoms and a new consolidation on the chest radiograph. In practice, diagnosis is challenging and 
misdiagnosis is common.(3) The gold standard is the detection of microorganisms in lung tissue, 
which is not practical and not available in the emergency department.  
When accuracy of chest radiographs for diagnosis of pneumonia have been evaluated, the 
agreement between clinicians and radiologists, or between two radiologists is often poor.(36,37) A 
recent study by Claessens has clarified these difficulties in diagnosis.(38) The French study examined 
319 patients with suspected CAP by chest radiograph and chest CT.(38) The results revealed a 
remarkable level of disagreement between x-ray, CT and clinical evaluation. In summary 1/3 of 
patients with a “normal” chest x-ray had an infiltrate on CT, and excluded CAP in 30% of patients 
with an apparent chest x-ray infiltrate.(38) Using CT as the gold standard, the diagnostic decision 
was changed in nearly 60% of cases.  
Unfortunately, routine use of CT for the diagnosis of pneumonia is unlikely to be widely available in 
the near future. Chest x-ray will remain the standard investigation. Nevertheless, as a result of this 
and other studies it is important to question the diagnosis of CAP, particularly when x-ray is 
equivocal, and to re-evaluate the accuracy of the diagnosis if patients do not respond to treatment 
as expected.(39)  
Lung ultrasound has been proposed as an alternative, and is attractive because ultrasound has 
become a routine skill for respiratory physicians in the management of pleural disease.(40-42)  
A systematic review of the use of lung ultrasound for diagnosis of CAP in adults concluded it has a 
sensitivity of 95%, specificity of 90% and that based on a final discharge diagnosis of CAP, it 
therefore had a superior sensitivity and similar specificity to chest x-ray.(42). A multicentre study by 
Reissig et al studied 229 patients with CAP. They found a sensitivity 93% and specificity of 98% but 
crucially found that approximately 8% of pneumonic lesions were not visible on ultrasound, 
indicating that lung ultrasound cannot be considered to exclude CAP.(43) 
A further recent systematic review and meta-analysis of 1172 patients investigated with ultrasound 
suggested the procedure took approximately 13 minutes to perform and had a sensitivity of 94%, 
specificity of 96%, therefore comparing favourably with alternative tests.(44) Studies were 
performed by highly skilled and trained sonographers, therefore limiting the applicability of this data 
beyond expert settings.  
Therefore in future, the diagnostic pathway for community-acquired pneumonia may include chest 
CT and/or thoracic ultrasound.  
A number of common and uncommon disorders can present initially with suspected community-
acquired pneumonia and an awareness of these possible alternative diagnoses is essential. These are 
summarised in Table 1. 
 
 
Diagnosis  Radiological features Clinical features 
Common   
Acute bronchitis (47) 
 
No X-ray changes Acute cough, without evidence of sepsis. May be a viral 
prodrome or accompanying viral symptoms 
Exacerbation of 
COPD(48) 
Hyperinflation and chronic 
changes but no 
consolidation 
History of COPD, cough, sputum and breathlessness with 
wheeze on examination.  
Exacerbation of 
asthma(49) 
May be hyperinflation, but 
no consolidation 
History of asthma, cough, breathlessness, wheeze. May 
be accompanied by viral prodrome 
Exacerbation of 
bronchiectasis(50) 
Often normal, mucus 
plugging may lead to 
opacities suggesting 
pneumonia 
Cough, sputum, breathlessness, chest pain, fever and 
malaise. Past history of bronchiectasis. 
Cardiac failure and 
pulmonary oedema (51) 
Cardiomegaly, pleural 
effusions, alveolar opacities 
(classically perihilar) upper 
lobe venous diversion 
Orthopnoea, Paroxysmal nocturnal dyspnoea, ankle 
oedema, absence of sepsis. Response to diuretics and 
nitrates. Often a past history of cardiac failure or cardiac 
disease. Elevated cardiac biomarkers but low 
inflammatory markers. 
Lung cancer/malignancy 
including lymphoma(52) 
Multiple possible imaging 
features 
Lack of inflammatory response, chronic symptoms, 
associated red flag symptoms (weight loss/haemoptysis) 
Non-respiratory 
sepsis(53) 
Severe sepsis from any 
source e.g UTI, 
intraabdominal, 
pancreatitis can be 
associated with 
consolidation (often 
bilateral) 
Initial history lacking in respiratory symptoms, clinical 
indicators of sepsis outside the respiratory tract. Isolation 
of pathogens not usually associated with CAP.  
Pulmonary 
embolism(54) 
Atelectasis, pleural 
effusion, elevated 
diaphragm, Westermarks 
sign, unilateral or bilateral 
opacities 
Difficult to differentiate clinically. Prominent 
hypoxaemia, pleuritic chest pain, collapse/syncope. 
Clinical evidence of DVT usually absent.  
Uncommon   
Acute interstitial 
pneumonia(55) 
Appearances similar to 
ARDS.  
Short history (often 1-2 weeks) cough, sputum, fever and 
progressive breathlessness.  
Cryptogenic organising 
pneumonia(56) 
Reversed halo sign, 
“flitting” shadows over 
time, concave opacities 
Relatively chronic course (usually >1 month) 
Chronic eosinophilic 
pneumonia(57) 
Bilateral nonsegmental 
consolidation with 
peripheral predominance 
Subacute or chronic presentation. Peripheral pulmonary 
infiltrates. Eosinophilia (peripheral or on BAL). More 
common in females than males.  
Acute eosinophilic 
pneumonia(58) 
Diffuse radiographic 
infiltrates 
Often occurs in young adults. Peripheral blood 
eosinophilia 
Lipoid pneumonia(59) Presence of fat within 
consolidation on CT.  
Non-specific presentation- Dyspnoea and cough 
Tuberculosis(60) Upper lobe changes, 
cavitation 
Chronic course, absence of sepsis, haemoptysis, weight 
loss, night sweats.  
Table 2. Differential diagnoses of community-acquired pneumonia in patients presenting to hospital 
or the emergency department. The list is no exhaustive but gives examples of differential diagnoses.  
 
The possibility of lung malignancy should be particularly considered in all patients presenting with 
CAP. Up to 10% of CAP patients admitted to hospital will be ultimately diagnosed with pulmonary 
malignancy.(52,61,62) In a cohort study in Canada of 3398 patients, lung cancer was diagnosed in 1% 
of patients at 12 months.(62) Lung cancer was most frequent in patients over the age of 50, men and 
smokers.(62) In a cohort study of 40,744 patients with CAP, Mortensen and colleagues 
demonstrated that the most important risk factors were a history of COPD, prior malignancy, white 
race and tobacco use.(61) The diagnosis should be considered in all patients, but particularly those 
over the age of 50 and with a history of cigarette smoking.  
 
Diagnosis of CAP in primary care 
In the community, diagnosis is even more challenging where the majority of acute respiratory 
infections are not investigated by chest x-ray.(63) Even where chest x-rays are performed, diagnosis 
may be missed. In a study of 12 European countries, 3% of 1885 patients with LRTI not thought to be 
pneumonia had CXR evidence of pneumonia on independent radiology review.(5) 
Biomarkers can assist in the diagnostic pathway. In a study in 12 European countries of 2820 
patients with lower respiratory tract infections, where x-rays were performed, 140 (5%) had 
pneumonia. Clinical features had a moderate ability to identify pneumonia, where pneumonia was 
more frequent with the absence of a runny nose, the presence of breathlessness, crackles, 
diminished breath sounds on auscultation, tachycardia and fever. Addition of CRP>30mg/L to this 
model greatly improved the diagnostic accuracy (from area under the curve 0.70 to 0.77).(64) 
Procalcitonin did not help diagnosis in this model.(64) 
Patients with radiologically proven pneumonia appear to derive benefit from antibiotic treatment. In 
a 12 country randomized controlled trial of amoxicillin for LRTI In primary care (n=1038 amoxillin, 
n=1023 placebo) there was no impact of antibiotics on duration of symptoms or symptom severity 
with the antibiotic treatment.(65) Nevertheless, in a post-hoc analysis of patients subsequently 
found to have radiological pneumonia, patients with x-ray changes treated with antibiotics had a 
more rapid resolution of symptoms and lower severity of symptoms.(5) 
Since x-ray is impractical in terms of detecting pneumonia in primary care on a routine basis, 
alternatives are needed. Current guidance recommends the use of point of care C-reactive protein 
(CRP) testing as an alternative.(66) Randomized controlled trials show that use of CRP can reduce 
antibiotic use for LRTI without adverse effects.(67,68) A cluster randomized controlled trial in the 
Netherlands showed that CRP could half with rate of antibiotic prescription. Recommended cut-offs 
vary but studies suggest a cut-off of 30mg/L is most accurate to predict pneumonia.(67-70)  
Thus in primary care a combination of clinical history, markers of severity such as the CRB65 scoring 
system(71,72), and the use of point of care CRP testing where available is most effective in 
identifying those patients requiring antibiotic treatment.  
 
CAP pathogens and diagnostic tests 
Once a diagnosis of CAP is made and empirical therapy is being considered or has been 
administered, the diagnostic process moves towards determining the underlying causative 
pathogen. Routine use of microbiological investigations in primary care is generally not 
recommended due to the low rate of true pneumonia among such patients. Nevertheless, it is 
known that the spectrum of pathogens in outpatients is very similar to those in inpatients.(72-74) 
There is some variation globally in the proportions of different pathogens reported as the causes of 
community-acquired pneumonia, but in general the list of pathogens is remarkably 
consistent.(16,75-78) In figure 2 we select representative cohort studies from North America, South 
America, Northern Europe, Southern Europe, Asia and Australasia, and demonstrate that the 
predominant pathogens are broadly similar.(75-78) Streptococcus pneumoniae remains the most 
frequently isolated bacterial pathogen in community-acquired pneumonia across the world which is 
why it is a focus of vaccination efforts.(79,80) Approximately 1/3 of patients with pneumococcal 
pneumonia will have bacteraemia.(81) It is controversial whether bacteraemia is associated with 
worse outcomes, and recent data suggests that bacteraemic infection may have different clinical 
characteristics but similar outcomes.(81,82) 
 
 Figure 2. Representative frequency of pathogens across Global CAP cohorts. Data from refs 12,75-78. 
Cohort were selected as being prospectively enrolled with standardised testing for organisms.  
 
The recent EPIC study supported by the Centre for Disease Control and Prevention in the United 
States has provided a clearer view of the aetiology of CAP in North America.(75) The study was 
conducted at 5 hospitals in Nashville and Chicago, USA.(75) 2488 patients were enrolled of which 
2320 had radiographic pneumonia. The study enrolled predominantly milder CAP patients, with an 
average age of 57 and 65% of patients being in PSI risk class 1-3, where patients would normally be 
treated as outpatients.(83) Extensive aetiological testing revealed a pathogen in 38%, with viruses 
being more frequent than bacteria. Rhinovirus was most frequently detected in 9% of patients, 
influenza in 6% and S. pneumoniae in 5%.(75) Other pathogens were infrequent (figure 2). This data 
suggests that viral infections may be more frequent than bacteria in mild CAP in the United 
States.(75)  
Co-infection is common across a number of studies.(84) The presence of a viral infection does not 
imply the absence of bacterial infection in patients with CAP.  
Most empirical regimes cover both typical and atypical pathogens and this is appropriate because 
studies suggest that atypical organisms are common throughout the world.(17,66) A study by Arnold 
et al identified rates of atypical pathogens to be 22% in North America, 28% in Europe, 21% in Latin 
America and 20% in Africa, justifying the universal use of atypical coverage.(85) Even in outpatients 
or patients in primary care it is common to identify atypical organisms and particularly Mycoplasma 
pneumoniae.(86) Consist observational data suggests that the addition of macrolide to beta-lactam 
therapy provides benefits in terms of reduced time to clinical stability and reduced mortality 
compared to beta-lactam alone.(87,88) This data is the basis of international guidelines 
recommendations to use atypical coverage in all inpatients, and particularly in patients with severe 
pneumonia.(17,66) 
In some geographical regions, the distinction between typical bacterial pneumonia and 
Mycobacterium tuberculosis (MTb) infection can be difficult, leading to MTb being listed as a cause 
of CAP. The United States Centre for Disease Control has listed 22 risk factors that can identify 
patients at high risk of MTb infection, and in patients with suspected CAP the five strongest risk 
factors were night sweats, weight loss, haemoptysis, prior exposure to MTb and upper lobe 
infiltrates, these all being classical of TB infection.(89) 
Diagnostic testing for the underlying cause is directed therefore against a range of pathogens most 
likely to be identified, or less common pathogens that would nevertheless change treatment such as 
the atypical organisms or multidrug resistant organisms.(90,91)  
 Standard cultures and urinary antigen testing 
Conventional culture based microbiology is still the mainstay of microbiological diagnosis. Most 
international CAP guidelines recommend blood cultures for patients on admission to hospital, ideally 
prior to antibiotic treatment.(17.66) Sputum culture is recommended in expectorating patients. 
Some guidelines such as the British Thoracic Society guidelines in the UK and subsequent NICE 
update recommend omitting microbiological investigations in patients with mild pneumonia.(66) 
This has potential advantages in terms of reducing costs, but has limitations in terms of identifying 
local microbiology patterns and also initial assessment of severity of disease is often unreliable. 
Most guidelines internationally suggest blood and sputum cultures in those patients to be treated as 
inpatients and this is the authors practice as well.  
Sputum cultures are most likely to be positive in patients with chronic respiratory diseases such as 
COPD, bronchiectasis and asthma.(92,93) Studies based largely on sputum cultures will report high 
frequencies of Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa for this 
reason, while studies based on alternative diagnostic tests will report these organisms less 
frequently as they are less commonly identified in the blood.(92-95)  
Urinary antigen testing for S. pneumoniae  and Legionella pneumophila have become standard care 
in many hospitals in the United States, Europe and internationally. (17,66) 
Urinary antigen testing for L. pneumophila are well established and have a sensitivity of 75-80% and 
a specificity approaching 100%. The limitation is that existing tests only identify L. pneumophila 
serogroup 1.(96)  
 
Detection of viruses and atypical organisms 
Atypical pathogens have characteristic clinical features, for example hyponatraemia, abnormal liver 
function tests, diarrhoea and very high levels of C-reactive protein in L. pneumophila 
infection.(97,98) None of the clinical prediction tools or individual clinical characteristics are 
sufficiently sensitive or specific to be used to guide antibiotic treatment. Therefore all patients 
should be considered for testing for atypical pathogens. Detection of rising IgM antibody titres to M. 
pneumoniae, L. pneumophila and other atypical pathogens has been long recommended in 
guidelines, but reported sensitivity is only 30-60% and can only be determined 
retrospectively.(97,98) It is therefore not useful to guide treatment. PCR is now the treatment of 
choice for detection of all atypical pathogens in throat or lower respiratory tract samples.(99,100) 
Viral diagnostics are increasingly used. Their value is in identifying patients who may benefit from 
anti-viral treatment such as neuraminidase inhibitors (while recognising the current controversy 
over the effectiveness or otherwise of these drugs) and for isolation of potential infectious 
patients.(101-103) Diagnostic immunoassays are available for use in throat swabs, sputum and 
bronchoalveolar lavage. Reported sensitivity ranges from 40-70% indicating that a negative assay 
cannot rule out the presence of influenza. PCR is the test of choice with a higher sensitivity and 
specificity and multiplex assays are available covering the majority of clinically important respiratory 
viruses. Differential influenza virokinetics across the respiratory tract means that samples can be 
negative in nasophayngeal or throat swabs but may be subsequently positive on sputum or BAL 
samples. As a result, lower respiratory tract samples should be preferred. (104-106) 
 
PCR for Streptococcus pneumoniae, including assessment of bacterial load 
Studies have shown a higher sensitivity of PCR for detection of S. pneumoniae in sputum compared 
to conventional culture.(107) Studies have generally used primers directed at the specific 
pneumolysin or LytA genes.(107-110) Reasons for improved sensitivity likely relate to the poor 
survival of S. pneumoniae in sputum samples and the fact that PCR can detect non-viable S. 
pneumoniae and other bacteria and so is not affected by prior antibiotic treatment.(107-111) 
Rello et al evaluated DNA load, based on quantitative PCR, in blood from patients with 
pneumococcal pneumonia and demonstrated a clear relationship between DNA load and septic 
shock, a finding that has been confirmed in two other studies where DNA load correlated with 
severity markers in pneumonia.(109) 
Therefore PCR assays targeting S. pneumoniae are more sensitive than culture, are not limited by 
the requirement for organisms to be viable and therefore for samples to be taken prior to antibiotic 
treatment, and preliminary evidence suggests quantification could provide valuable prognostic 
information. This has not yet entered clinical practice but holds some promise.  
 
Emerging technologies 
Although microbiome sequencing has been successful applied to chronic respiratory diseases using 
sputum and bronchoalveolar lavage, there are limited data in CAP patients.(112-114) This 
technology that sequences all of the bacterial species present In a sample has potential, but is 
unlikely to reach routine clinical practice due to the bioinformatics challenges associated with 
analysis of the huge datasets.  
 
Biomarkers to guide diagnosis and antibiotic treatment 
Biomarkers have a limited role in the diagnosis of CAP as none are specific for pneumonia, as they 
are raised in other causes of systemic bacterial infection.(115) Nevertheless, C-reactive protein is 
raised in the majority of patients with CAP.(45) White blood cell count is unhelpful, as although it is 
often raised it is non-specific.  
PCT has been the most intensively studied as a marker that is rapidly upregulated in the presence of 
bacterial infection or inflammatory cytokines including interleukin 1 beta, IL-6 and TNF alpha.(115) 
Viral infections do not generate a strong PCT response leading to the suggestion that PCT can be 
used to identify infections likely to respond to antibacterial treatment. A number of trials have been 
conducted comparing biomarker guided treatment with standard care. In the largest of these, the 
ProHOSP study conducted in Switzerland, an algorithm comparing PCT with standard care (N=1381) 
resulted in a reduction in antibiotic use of 35% while being non-inferior in terms of clinical 
outcomes.(116) The study included patients with a range of respiratory tract infections. The impact 
in the subgroup with community-acquired pneumonia (N=460 randomized to PCT and 465 
randomized to standard care) was that 10% of CAP patients could be managed without antibiotics, 
with a reduction in duration of therapy in total of 3.5 days.(116)  
Limitations include that the duration of antibiotic treatment reported in the control arm was long 
(10 days on average) and might have been reduced with a simple antibiotic stewardship programme 
rather than a biomarker intervention, and secondly that the greatest value of PCT was in early 
stopped of antibiotics rather than the initial diagnostic decision.(117,118) 
A real life intervention based on PCT also in Switzerland and also France and the United States 
recruited 1759 patients, demonstrated that implementation of PCT reduced antibiotic treatment by 
1.5 days with no increase in adverse events.(119)  
A large number of other biomarkers have been evaluated to aid the diagnostic and prognostic 
decision making process in CAP. The most frequently evaluated have been CRP, PCT, 
Proadenomedullin (ProADM) and Copeptin.(115) 
C-reactive protein has little value in initial diagnosis in secondary care as levels as low as <10mg/L 
can be detected in patients with CAP.(45) There is only a weak relationship between CRP and 
severity of disease, but little added value of CRP over and above severity scoring systems.(45) 
Nevertheless, CRP is highly effective as a means of assessing treatment response. Mortality is <1% in 
patients where CRP has falled by 50% or more at day 3 or day 4.(120,121)  
Similarly, Proadrenomedullin has been extensively studied.(122) In a German study of 728 patients, 
it was the most accurate in evaluating prognosis (patients with the highest levels had a 3.7x 
increased risk of death) with an area under the curve of 0.81 which was better than the CRB65 
score.(122)  Independent studies have confirmed the prognostic accuracy of this biomarker. A study 
by Albrich found that adding ProADM to CURB65 enhanced outcome prediction but there are no 
studies to date showing that implementation of ProADM improve outcome in clinical practice.(123)   
 
Clinical utility of diagnostic testing: improving outcomes and antimicrobial stewardship 
An accurate diagnosis of CAP is important to reduce inappropriate antibiotic use in the context of both 
primary care and in secondary care. Inaccurate diagnosis of pneumonia and therefore inappropriate 
antibiotic treatment contributes to antibiotic resistance and to hospital acquired infections such as 
Clostridium difficile, a major problem in Western countries.(124,125) Once the diagnosis is made, 
identification of the causative pathogen allows de-escalation of treatment.(15) Van der Eerden 
demonstrated that pathogen directed therapy, using a combination of Gram-stain and clinical 
features, allowed de-escalation of treatment without compromising clinical outcomes.(126)  
Summary 
Despite its limitations, Chest x-ray remains the essential diagnostic test to identify CAP in secondary 
care. In primary care, the diagnosis remains clinical, but CRP measurement at point of care can be 
valuable to identify those patients requiring antibiotic treatment. Patients in secondary care should 
have a full battery of available microbiological tests including sputum and blood cultures, PCR for 
atypical organisms, viruses and urinary antigen testing.  
Developments in PCR technology in particularly promises to improve diagnostic and prognostic 
assessment in CAP in the future.  
 
References 
1. Drikoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin 
Microbiol Infect 2014;suppl5:45-51. 
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of 
death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of 
Disease Study 2010. Lancet 2012;380(9859):2095-128. 
3. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and 
inappropriate utilization of antibiotics: side effects of 4-h antibiotic administration rule. 
Chest 2007;131(6):1865-9. 
4. Taylor JK, Fleming GB, Singanayagam A, Hill AT, Chalmers JD. Risk factors for aspiration in 
community-acquired pneumonia. Analysis of a hospitalized UK cohort. Am J Med 2013; 
126(11):995-1001. 
5. Teepe J, Little P, Elshof N et al. Amoxiicillin for clinically unsuspected pneumonia in primary 
care : subgroup analysis. Eur Respir J 2016:47(1):327-30. 
6. MacFarlane J. Lower respiratory tract infection and pneumonia in the community. Semin 
Respir Infect 1999;14(2):151-62. 
7. Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in 
outpatients with community-acquired pneumonia. QJM 2011; 104(10):871-9. 
8. Lim HF, Phua J, Mukhopadhyay A et al. IDSA/ATS minor criteria aid pre-intensive care unit 
resuscitation in severe community-acquired pneumonia. Eur Respir J 2014;43(3):852-62. 
9. Salih W, Schembri S, Chalmers JD. Simplification of the IDSA/ATS criteria for severe 
community-acquired pneumonia. Eur Respir J 2014;43(3):842-51. 
10. Liapikou A, Cilloniz C, Gabarrus A et al. multilobar bilateral and unilateral chest radiograph 
involvement: implications for prognosis in hospitalised community-acquired pneumonia. Eur 
Respir J 2016;48(1):257-61. 
11. Sterrantino C, Trifiro G, Lapi F et al. Burden of community-acquired pneumonia in Italian 
General Practice. Eur Respir J 2013;42(6):1739-42. 
12. Chalmers JD, Hill AT. Investigation of non-resolving presumed lower respiratory tract 
infection in primary care. BMJ 2011; 343:d5840. 
13. Singanayagam A, Chalmers JD. The evidence for severity assessment tools to guide empirical 
antibiotic prescribing decisions in community-acquired pneumonia. Lancet Respiratory 
Medicine 2013;1(8):653-62. 
14. Postma DF, van Werkhoven CH, van Elden LJ et al antibiotic treatment strategies for 
community-acquired pneumonia in adults. N Engl J Med 2015;372(14):1312-23 
15. Carugati M, Franzetti F, Wiemken T et al. De-escalation therapy among bacteraemic patients 
with community-acquired pneumonia. Clin Microbiol Infect 2015;21(10):936:e11-8.  
16. Aliberti S, Cillonez C, Chalmers JD, Torres A, Blasi F. Multidrug-resistant pathogens in 
hospitalized patients coming from the community with pneumonia: a European perspective. 
Thorax 2013; 68(11):997-9.  
17. Mandell, LA, Wunderink, RG, Anzueto, A et al. Infectious Diseases Society of 
America/American Thoracic Society consensus guidelines on the management of 
community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27–S72 
18. Mandal P, Chalmers JD, Choudhury G, Akram AR, Hill AT. Vascular complications are 
associated with poor outcome in community-acquired pneumonia. QJM 2011;104(6):489-95. 
19. American Thoracic Society Infectious Diseases Society of America. Guidelines for the 
management of adults with hospital-acquired, ventilator-associated, and healthcare-
associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416 
20. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Mandal P, Choudhury G, Akram AR, Hill 
AT. Epidemiology, antibiotic therapy and clinical outcomes in healthcare associated 
pneumonia: a UK cohort study. Clin Infect Dis. 2011; 53(2):107-13. 
21. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S. Tarsia P, 
Mantero M, Blasi F. Stratifying risk factors for multi-drug resistant pathogens in hospitalized 
patients coming from the community with pneumonia. Clin Infect Dis. 2012;54 (4):470-8.  
22. Welte T, Torres A, Nathwani D. Clinical and economical burden of community acquired 
pneumonia among adults in Europe. Thorax 2012;67:71-79 
23. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare associated pneumonia does not 
accurately identify potentially resistant pathogens: a systematic review and meta-analysis. 
Clinical Infectious Diseases 2014; 58(3):330-9. 
24. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS, Epidemiology and outcomes of 
health-care-associated pneumonia: results from a large US database of culture-positive 
pneumonia, Chest 2005; 128(6); 3854–3862. 
25. Cilloniz C, Torres A, Polverino E et al. Community-acquired lung respiratory infections in HIV-
infected patients: microbial aetiology and outcome. Eur Respir J 2014;43(6):1698-708.  
26. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and 
health-care-associated pneumonia. Lancet Infect Dis. 2010; 10(4):279-87. 
27. Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity 
and related disorders. Eur Respir J 2015;46(6):1781-95. 
28. Ewig S, Klapdor B, Pletz MW et al. Nursing-home acquired pneumonia in Germany: an 8 year 
prospective multicentre study. Thorax 2012;67(2):132-8. 
29. Polverino E, Drambrava P, Cilloniz C et al. Nursing home acquired pneumonia: a 10 year 
single-centre experience. Thorax 2010;65(4):354-9. 
30. Self WH, Wunderink RG, Williams DJ et al. Staphylococcus aureus community-acquired 
pneumonia. Prevalence, clinical characteristics and outcomes. Clin Infect Dis 2016; in press 
31. Jones BE, Jones MM, Huttner B et al. Trends in antibiotic use and nosocomial pathogens in 
hospitalized veterans with pneumonia at 128 Medical Centers, 2006-2010. Clin Infect Dis 
2015;61(9):1403-10. 
32. Dobbler CC, Waterer G. Healthcare-associated pneumonia: a US disease or relevant to the 
Asia pacific too? Respirology 2013;18(6):923-32. 
33. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-
resistant bacteria by select risk factors for health care-associated pneumonia, Arch Intern 
Med 2008; 168(20); 2205–2210. 
34. Prina E, Ranzani OT, Polverino E et al. Risk factors associated with potentially antibiotic 
resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12(2):153-
60. 
35. Jeong BH, Koh WJ, Yoo H et al. Risk factors for acquiring potentially drug resistant pathogens 
in immunocompetent patients with pneumonia developed out of hospital. Respiration 
2014;88(3):190-8. 
36. Campbell SG, Murray DD, Hawass A et al. Agreement between emergency physician 
diagnosis and radiologist reports in patients discharged from an emergency department with 
community-acquired pneumonia. Emerg Radiol 2005;11(4):242-6.  
37. Chandra A, Nicks B, Maniago E et al. A multicenter analysis of the ED diagnosis of 
pneumonia. Am J Emerg Med 2010;28(8):862-5. 
38. Claessens YE, Debray MP, Tubach F et al. Early chest computed tomography scan to assist 
diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J 
Respir Crit Care Med 2015;192(8):974-82. 
39. Goncalves-Pereira J, Conceicao C, Povoa P. Community-acquired pneumonia: Identification 
and evaluation of nonresponders. Ther Adv Infect Dis 2013;1(1):5-17. 
40. Bhatnagar R, Corcoran JP, Maldonando F et al. Advanced medical interventions in pleural 
disease. Eur Respir Rev 2016;25(140):199-213. 
41. Reali F, Sferrazza Papa GF, Carlucci P et al. can lung ultrasound replace chest radiography for 
the diagnosis of pneumonia in hospitalised children? Respiration 2014;88(2):112-5. 
42. Ye X, Xiao H, Chen B, Zhang S. Accuracy of Lung Ultrasonography versus chest radiography 
for the diagnosis of adult community-acquired pneumonia: review of the literature and 
meta-analysis. Plos One 2015;10(6):e0130066. 
43. Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, et al. Lung ultrasound in the diagnosis 
and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic 
accuracy study. Chest 2012; 142: 965–972. 
44. Chavez MA, Shams N, Ellington LE et al. Lung ultrasound for the diagnosis of pneumonia in 
adults: a systematic review and meta-analysis. Respir Res 2014;15:50. 
45. Chalmers JD, Singanayagam A, Hill AT. C- reactive protein is an independent predictor of 
severity in community acquired pneumonia. Am J Med 2008;121(3):219-225. 
46. Chalmers JD, Singanayagam A, Scally C, Hill AT. Admission D-Dimer can identify low risk 
patients with community acquired pneumonia. Ann Emerg Med. 2009; 53(5);633-8. 
47. Llor C, Bjerrum L. Antibiotic prescribing for acute bronchitis. Expert Rev Anti Infect Ther 
2016;14(7):633-42. 
48. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with 
acute exacerbation of chronic obstructive pulmonary disease. Annals of the American 
Thoracic Society 2013; 10(2):81-9. 
49. Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 2016; 
47(6):1680-6. 
50. Chalmers JD, Aliberti S, Blasi F. State of the art: management of bronchiectasis in adults. Eur 
Respir J 2015; 45(5):1446-62. 
51. Kapoor JR, Kapoor R, Ju C et al. Precipitating clinical feactures, heart failure characterisation 
and outcomes in patients hospitalized with heart failure with reduced borderline and 
preserved ejection fraction. JACC Heart Fail 2016;4(6):464-72. 
52. Shepshelovich D, Goldvaser H, Edel Y et al. High lung cancer incidence in heavy smokers 
following hospitalization due to pneumonia. Am J Med 2016;129(3):332-8. 
53. Aliberti S, Brambilla AM, Chalmers JD, et al. Phenotyping community-acquired pneumonia 
according to the presence of acute respiratory failure and severe sepsis. Respir Res 
2014;15:27.  
54. Alves dos Santos JW, Torres A, Michel GT et al. Non-infectious and unusual infectious mimics 
of community-acquired pneumonia. Respir Med 2004;98(6):488-94. 
55. Bonaccorsi A, Cancellieri A, Chilosi M et al. Acute interstitial pneumonia: report of a series. 
Eur Respir J 2003;21(1):187-91. 
56. Kastelik JA, Greenstone M, McGivern DV, Morice AH. Crytogenic organising pneumonia. Eur 
Respir J 2006;28(6):1291. 
57. Oyama Y, Fujisawa T, Hashimoto D et al. Efficacy of short-term prednisolone treatment in 
patients with chronic eosinophilic pneumonia. Eur Respir J 2015;45(6):1624-31. 
58. Rhee CK, Min KH, Yim NY et al. Clinical characteristics and corticosteroid treatment of acute 
eosinophilic pneumonia.  Eur Respir J 2013;41(2):402-9. 
59. Kuroyama M, Kagawa H, Kitada S et al. Exogenous lipoid pneumonia caused by repeated 
sesame oil pulling: report of two cases. BMC Pulm Med 2015;15:135. 
60. Wang JY, Lee CH, Yu MC et al. Fluoroquinolone use delays tuberculosis treatment despite 
immediate mycobacteriology study. Eur Respir J 2015;46(2):567-70. 
61. Kang KL, Eurich DT, Minhas-Sandhu JK et al. Incidence, correlates and chest radiographic 
yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med 
2011;171(13):1193-8. 
62. Mortensen EM, Copeland LA, Pugh MJ et al. Diagnosis of pulmonary malignancy after 
hospitalization for pneumonia. Am J Med 2010;123(1):66-71. 
63. Goossens H, Little P. Community-acquired pneumonia in primary care. BMJ 
2006;332(7549):1045-6. 
64. Van Vugt SF, Broekhuizen BD, Lammens C et al. Use of serum C-reactive protein and 
procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in 
patients presenting to primary care with acute cough: diagnostic study. BMJ 2013;356:f2450. 
65. Little P, Stuart B, Moore M et al. Amoxicillin for acute lower-respiratory tract infection in 
primary care when pneumonia is not suspected: a 12-country randomised placebo 
controlled trial. Lancet Infect Dis2013;13(2):123-9.  
66. Eccles S, Pincus C, Higgins B et al. Diagnosis and management of community and hospital 
acquired pneumonia in adults, Summary of NICE guidance. BMJ 2014;349:g6722. 
67. Little P, Stuart B, Francis N et al effects of internet-based training on antibiotic prescribing 
rates for acute respiratory-tract infections: a multinational cluster randomised factorial 
controlled trial. Lancet 2013;382(9899):1175-82. 
68. Cals JW, Butler CC, Hopstaken RM, et al. Effect of point of care testing for C-reactive protein 
and training in communication skills on antibiotic use in lower respiratory tract infections: 
cluster randomised trial. BMJ 2009;338:b1374. 
69. Minnaard MC, van de Pol AC, Hopstaken RM et al. C-reactive protein point-of-care testing 
and associated antibiotic prescribing. Fam Pract 2016; in press.  
70. Huang Y, Chen R, Wu T et al. Association between point-of-care CRP testing and antibiotic 
prescribing in respiratory tract infections: a systematic review and meta-analysis of primary 
care studies. Br J Gen Pract 2013;63(616):e787-94. 
71. Singayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: 
a review. QJM 2009; 102(6):379-88. 
72. Choudhury G, Mandal P, Akram AR, Murray MP, Short PM, Singanayagam A, Hill AT. 
Physician Judgement is a crucial adjunct to pneumonia severity scores in low risk patients. 
Eur Respir J 2011; 38(3):643-8. 
73. Cilloniz C, Ewig S, Polverino E et al. Community-acquired pneumonia in outpatients: 
aetiology and outcomes. Eur Respir J 2012;40(4):931-8. 
74. Cilloniz C, Gabarrus A, Almirall J et al. Bacteraemia in outpatients with community-acquired 
pneumonia. Eur Respir J 2016;47(2):654-7. 
75. Jain S, Self WH, Wunderink RG et al. Community-acquired pneumonia requiring 
hospitalization among US adults. N Engl J Med 2015;373(5):415-27. 
76. Charles PG, Whitby M, Fuller AJ et al. The etiology of community-acquired pneumonia in 
Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin 
Infect Dis 2008;46(10):1513-21. 
77. Takaki M, Nakama T, Ishda M et al. High incidence of community-acquired pneumonia 
among rapidly aging population in Japan: a prospective hospital-based surveillance. Jpn J 
Infect Dis 2014;67(4):269-75. 
78. Luna CM, Famiglietti A, Absi R et al. Community-acquired pneumonia: etiology, 
epidemiology and outcome at a teaching hospital in Argentina. Chest 2000;118(5):1344-54. 
79. Galanis I, Lindstrand A, Darenberg J et al. Effects of PCV7 and PCV13 on invasive 
pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J 2016;47(4):1208-18. 
80. Mangen MJ, Rozenbaum MH, Huijts SM et al. Cost-effectiveness of adult pneumococcal 
conjugate vaccination in the Netherlands. Eur Respir J 2015;46(5):1407-16. 
81. Amaro R, Liapikou A, Cilloniz C et al. Predictive and prognostic factors in patients with blood-
culture-positive community-acquired pneumococcal pneumonia. Eur Respir J 2016 May 12. 
pii: ERJ-00039-2016. doi: 10.1183/13993003.00039-2016. [Epub ahead of print] 
82. Torres A, Cilloniz C, Ferrer M et al. Bacteraemia and antibiotic-resistant pathogens in 
community-acquired pneumonia: risk and prognosis. Eur Respir J 2015;45(5):1353-63. 
83. Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-
acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011; 37(4):858-64. 
84. Cilloniz C, Civjak R, Nicolini A, Torres A. Polymicrobial community-acquired pneumonia: an 
emerging entity. Respirology 2016;21(1):65-75. 
85. Arnold FW, Summersgill JT, Lajoie AS et al. A worldwide perspective of atypical pathogens in 
community-acquired pneumonia. Am J Respir Crit Care Med 2007;175(10):1086-93. 
86. Yuan X, Liu Y, Bai C et al. Mycoplasma pneumoniae infection is associated with subacute 
cough. Eur Respir J 2014;43(4):1178-81. 
87. Sigli WI, Asadi L, Eurich DT et al. Macrolides and mortality in critically ill patients with 
community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 
2014;42(2):420-32. 
88. Asadi L, Sligi WI, Eurich DT et al. Macrolide based regimens and mortality in hospitalised 
patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin 
Infect Dis 2012;55(3):371-80. 
89. Cavallazzi R, Wiemkin T, Christensen D et al. Predicting Mycobacterium tuberculosis in 
patients with community-acquired pneumonia.  Eur Respir J 2014;43(1):178-84.  
90. Burgos J, Lujan M, Larrosa MN et al. The problem of early mortality in pneumococcal 
pneumonia: a study of risk factors. Eur Respir J 2015;46(2):561-4. 
91. Browall S, Backhaus E, Naucler P, Galanis I et al. Clinical manifestations of invasive 
pneumococcal disease by vaccine and non-vaccine types. Eur Respir J 2014;44(6):1646-57. 
92. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of 
the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. 
Ann Am Thorac Soc 2015; 12(11):1602-11. 
93. Rodrigo-Troyano A, Suarez-Cuartin G, Peiro M et al. Pseudomonas aeruginosa resistance 
patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology 2016 in 
press. 
94. Chalmers JD, Smith MP, McHugh B, Doherty C, Govan JRW, Hill AT. Short and long term 
antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J 
Respir Crit Care Med. 2012; 186(7):657-65. 
95. Sibila O, Garcia-Bellmunt L, Giner J et al. Airway mucin 2 is decreased in patients with severe 
Chronic obstructive pulmonary disease with bacterial colonization. Ann Am Thorac Soc 
2016;13(5):636-42. 
96. Botelho-Nevers E, Grattard F, Viallon A et al. Prospective evaluation of RT-PCR on sputum 
versus culture, urinary antigens and serology for Legionnaires disease diagnosis. J Infect 
2016;73(2):123-8. 
97. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, Lortholary O, Zumla A, Abubakar 
I. Epidemiology and clinical management of Legionnaires' disease. Lancet Infect Dis. 
2014;14(10):1011-21. 
98. Murdoch DR, Podmore RG, Anderson TP, et al. Impact of routine systematic polymerase chain 
reaction testing on case finding for Legionnaires’ disease: a pre-post comparison study. Clin 
Infect Dis 2013; 57:1275–1281. 
99. Thurman KA, Walter ND, Schwartz SB, Mitchell SL, Dillon MT, Baughman AL , et al. Comparison 
of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community 
outbreaks. Clin Infect Dis 2009;48:1244–1249. 
100. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia 
pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007;44:568-76. 
101. Lee N, Leo YS, Cao B et al. Neuraminidase inhibitors, superinfection and 
corticosteroids affect survival of influenza patients. Eur Respir J 2015;45(6):1642-52. 
102. Ho PL, Sin WC, Chan JF et al. Severe influenza H7N9 pneumonia with rapid virological 
response to intravenous zanamivir. Eur Respir J 2014;44(2):535-7. 
103. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing 
and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 
2009;339:b5106. 
104. Chan MC, Lee N, Ngai KL, Leung TF, Chan PK. Clinical and virologic factors associated 
with reduced sensitivity of rapid influenza diagnostic tests in hospitalized elderly patients and 
young children. J Clin Microbiol. 2014;52(2):497-501. 
105. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza 
diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156(7):500-11. 
106. Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, et al. High morbidity and mortality in 
adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069-
77. 
107. Lorente, ML, Falguera, M, Nogués, A, González, AR, Merino, MT, Caballero, MR. 
Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a 
prospective clinical study. Thorax. 2000; 55: 133-137. 
108. Peters, RP, de Boer, RF, Schuurman, T, et al. Streptococcus pneumoniae DNA load in 
blood as a marker of infection in patients with community-acquired pneumonia. J Clin 
Microbiol 2009; 47: 3308-3312. 
109. Rello, J, Lisboa, T, Lujan, M et al. Severity of pneumococcal pneumonia associated with 
genomic bacterial load. Chest. 2009; 136: 832-840.   
110. Cremers, AJ, Hagen, F, Hermans, PW, Meis, JF, Ferwerda, G. Diagnostic value of serum 
pneumococcal DNA load during invasive pneumococcal infections. Eur J Clin Microbiol Infect 
Dis. 2014; 33: 1119-1124. 
111. Resti, M, Moriondo, M, Cortimiglia, M, et al. Community‐acquired bacteremic 
pneumococcal pneumonia in children: diagnosis and serotyping by real‐time polymerase 
chain reaction using blood samples. Clin Infect Dis. 2010; 51: 1042-1049. 
112. Simpson JL, Daly J, Baines KJ et al. Airway dysbiosis: Haemophilus influenzae and 
tropheryma in poorly controlled asthma. Eur Respir J 2016;47(3):792-800. 
113. Smith DJ, Badrick AC, Zakrzewski M et al. Pyrosequencing reveals transient cystic 
fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J 2014;44(4):922-
30. 
114. Wang Z, Bafadhel M, Haldar K et al. Lung microbiome dynamics in COPD 
exacerbations. Eur Respir J 2016; 47(4):1082-92.  
115. Viasus D, Del Rio-Pertuz G, Simonetti AF et al. Biomarkers for predicting short-term 
mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect 
2016;72(3):273-82. 
116. Schuetz P, Christ-Crain M, Thomann R  et al. Effect of procalcitonin-based guidelines 
vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP 
randomised controlled trial. JAMA 2009;302(10):1059-66. 
117. Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill AT. 7 day 
antibiotic courses have similar efficacy to prolonged courses in severe community acquired 
pneumonia- a propensity-adjusted analysis. Clinical Microbiology and Infection 
2011;17(12):1852-8.  
118. Murray C, Shaw A, Lloyd M, Smith RP, Fardon TC, Schembri S, Chalmers JD. A 
multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract 
infections. J Antimicrob Chemother 2014; 69(2):515-8. 
119. Albrich WC, Dusemund F, Bucher B et al. Effectiveness and safety of procalcitonin-
guided antibiotic therapy in lower respiratory tract infections in “real life” : an international 
multicenter poststudy survey (PROREAL). Arch Intern Med 2012;172(9):715-22. 
120. Akram AR, Chalmers JD, Taylor JK, et al. An evaluation of clinical stability criteria to 
predict hospital course in community-acquired pneumonia. Clin Microbiol Infect 
2013;19(12):1174-80. 
121. Menendez R, Martinez R, Reyes S et al. Stability in community-acquired pneumonia: 
one step forward with markers? Thorax 2009;64(11):987-92. 
122. Kruger S, Ewig S, Giersdorf S et al. Cardiovascular and inflammatory biomarkers to 
predict short and long term survival in community-acquired pneumonia. Am J Respir Crit 
Care Med 2010;182(11):1426-34. 
123. Albrich WC, Dusemund F, Ruegger K et al. Enhancement of CURB65 score with 
Proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: 
derivation of a clinical algorithm. BMC Infect Dis. 2011;11:112. 
124. Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of 
lower respiratory tract infections in response to the Clostridium difficile epidemic. J 
Antimicrob Chemother 2010; 65(4):608-18. 
125. Chalmers JD, Akram AR, Singanayagam A et al. Risk factors for Clostridium difficile 
infection in hospitalized patients with community-acquired pneumonia. J Infect 
2016;73(1):45-53. 
126. Van der Eerden MM, Vlaspolder F, de Graaff CS et al. Comparison between pathogen 
directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients 
with community-acquired pneumonia: a prospective randomised study. Thorax 
2005;60(8):672-8. 
 
